AstraZeneca and Oxford University jointly developed COVID-19 vaccine-induced immune response in older adults in their phase 2 trial, the British drug makers confirmed Thursday.
“AstraZeneca phase 2 study does not assess efficacy against COVID-19. “
“Results of phase 3 AstraZeneca vaccine trial expected in weeks.”
But it does little to impress to markets, which are unnerved by the growth of covid cases and new shutdowns across the globe.
S&P 500 futures stall its recovery, trading at 3,570, up 0.11% so far.